Internal medicine

Open label

Methylation

Gene

Oncology

Chemistry

Cyclophosphamide

Temozolomide

Glioblastoma

Chemotherapy

Vincristine

Lomustine

O-6-methylguanine-DNA methyltransferase

Cancer research

Clinical trial

Biochemistry

Medicine

Methyltransferase

The Lancet

Our results suggest that lomustine-temozolomide chemotherapy might improve survival compared with temozolomide standard therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter. The findings should be interpreted with caution, owing to the small size of the trial.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial